







**REGENERATIVE MEDICINE  
(REMEDIC)**

Standing Committee for the Medical Sciences  
(European Medical Research Councils, EMRC)



# Introduction

The European Science Foundation (ESF) is an independent, non-governmental organisation of national research organisations.


Our strength lies in the membership and in our ability to bring together the different domains of European science in order to meet the scientific challenges of the future. ESF's membership currently includes 77 influential national funding agencies, research-performing agencies and academies from 30 nations as its contributing members.

Since its establishment in 1974, ESF, which has its headquarters in Strasbourg with offices in Brussels and Ostend, has assembled a host of research organisations that span all disciplines of science in Europe, to create a common platform for cross-border cooperation.

We are dedicated to supporting our members in promoting science, scientific research and science policy across Europe. Through its activities and instruments ESF has made major contributions to science in a global context. The ESF covers the following scientific domains:

- Humanities
- Life, Earth and Environmental Sciences
- Medical Sciences
- Physical and Engineering Sciences
- Social Sciences
- Marine Sciences
- Nuclear Physics
- Polar Sciences
- Radio Astronomy Frequencies
- Space Sciences

The European Medical Research Councils (EMRC) is the membership organisation for all the medical research councils in Europe under the ESF. Its mission is to promote innovative medical research and its clinical application towards improved human health. EMRC offers authoritative strategic advice for policy making, research management, ethics and better health services.



Cover pictures: Mesenchymal stem (stromal) cells differentiating to cartilage (left column) and to cardiomyocyte-like cells (right column). Chondrocyte marker in A is aggrecan (red) and cardiomyocyte marker in D is Nkx2.5 (green). Chondrocyte nuclei in B were counterstained with 4,6-diamidino-2-phenylindole (blue) and the cardiomyocyte nuclei in E were counterstained with propidium iodide (red). The last images, C and F, represent an overlay of respectively, A&B and D&E. Li W. *et al.*: Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 25:2118-27, 2007. AlphaMed Press.

Regenerative medicine, a rapidly evolving and exciting field, can be defined as the process of creating living, functional tissues to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. This can be done through a variety of approaches including the replacement of tissue function with synthetic constructs (artificial organs) and using cellular therapies such as stem cells or genetically modified cells to generate new tissues and organs. Today, there is an enormous need for regenerative medicine therapies as is evident, to take only one example, of the high number of heart transplantations, 75,000 of which are undertaken worldwide each year<sup>1</sup>. Their number is limited by the lack of appropriate donors and due to the heavy regime, such treatment is not easy to administer to the elderly people who most urgently need it. Less invasive treatment to enable heart regeneration with stem cells would be welcome.

Recent advances in stem cell technologies, including for example the ability to induce human pluripotent stem (iPS) cells, mark a new era for regenerative medicine<sup>2</sup>. Stem cells have an almost unlimited proliferation potential accompanied by an ability to differentiate. Thus, hematopoietic stem cells (HSCs – that give rise to the various blood cell types, including neutrophils and erythrocytes) and mesenchymal stem (or stromal) cells (MSCs – that give rise to many cell types, including adipocytes and chondrocytes) form an essential element in regenerative (or reparative) medicine, including guided regeneration.

This field has the potential to allow either the self-repair of damaged tissues and organs or generation of new tissues and organs to be used in transplantations.




Figure 1. A bioreactor in which naïve or modified stem cells are allowed under controlled circumstances to differentiate and produce extracellular matrix (or resorb or otherwise modify their scaffold) before implantation to the recipient. Courtesy of Prometheus (Skeletal Tissue Engineering Division) – Katholieke Universiteit Leuven (K.U.Leuven), Belgium.



Figure 2. Surgical implantation of a regenerative medicine device is done under aseptic conditions. Courtesy of Prometheus (Skeletal Tissue Engineering Division) – Katholieke Universiteit Leuven (K.U.Leuven), Belgium.

Using the versatile genetic information stored within the cell nuclei, from where it is transcribed (copied) and then translated into proteins, is an intelligent way to regulate the repair of cells, tissues and organs. Importantly, regenerative medicine also has the potential to solve the problem of the shortage of organs available for donation compared to the number of patients that require life-saving organ transplantation.

When multipotent stem cells such as HSCs and MSCs are harvested from autologous sources (i.e. using the patient's own cells), immunological rejection and the burden of the use of immunosuppressive (cytotoxic) drugs are avoided. Endogenous stem cells can be activated with proper growth and differentiation stimuli to maintain or augment bodily functions. For example, subcutaneous fat tissue forms an autologous MSC source, which can be simply collected using a needle for fat aspiration. Cells isolated are allowed to expand and then driven to differentiate as such, in tissue engineering devices or bioreactors (Figure 1) before application back to body as cells, tissues or organs, either locally by surgical procedure (Figure 2) or systemically by injection. They help the target site(s) to regenerate so that structure and function are not replaced, but restored.

Another possible application is in wound repair, a complex biological process that occurs during most of our lives. Often, in adults, the wound repair process leads to a once functional tissue becoming a non-functioning mass of fibrotic tissue, more commonly known as a scar. In contrast, injuries that occur during pre-natal development are completely healed, an ability that is lost during adulthood. One approach would be to insert adult stem cells from the patient into a biometric matrix

within the wound, recreating the prenatal environment and thus stimulating tissue regeneration<sup>3</sup>. Although, the development of this form of treatment may seem distant, the individual elements of this approach have been demonstrated *in vitro* and *in vivo*.

Furthermore, using HSCs and MSCs raises less ethical concerns than the use of embryonic stem cells for the moment. Autologous stem cells have a known source of origin and as such cannot transmit any new infections or prions to the recipient. Such cells can be used at once or stored in biobanks for eventual future use. The versatility of cell-based therapies can be enhanced by genetic manipulation of the cells in the laboratory, like for example, coding of a missing protein such as a hormone or enzyme which would last for the lifetime of the recipient<sup>4</sup>. For experimental work, markers useful in tracing of the transferred cells can be added to study their long term fate (Figure 5).

As our knowledge advances, the frontiers of regenerative medicine are rapidly expanding. Regenerative medicine provides new insights in areas including cellular proliferation, effects of humoral and matrix signalling on cells, angiogenesis, tissue remodelling, naïve and adaptive immunity and other basic processes in cell biology. Still, regenerative medicine is in its infancy and to advance progress in this important field, national funding agencies from 13 European countries have joined forces to launch a cross-disciplinary Research Networking Programme, REMEDIC, to identify where the frontiers and future needs are in this complex multidisciplinary high-technology field, by networking researchers and clinicians across Europe.

The running period of the ESF REMEDIC Research Networking Programme is for five years from May 2008 to May 2013 (07-RNP-128).

## References

1. Chien K. R. Regenerative medicine and models of human disease, *Nature* **453**, 302-305 (2008).
2. Yu J., *et al.* Induced pluripotent stem cell lines derived from human somatic cells, *Science*, **318**, 1917-1920 (2007).
3. Gurtner G. C., *et al.* Wound repair and regeneration, *Nature* **453**, 314-321 (2007).
4. Kaye D. M., *et al.* Reversing advanced heart failure by targeting  $Ca^{2+}$  cycling, *Annu. Rev. Med.* **59**, 13-28 (2008).



# Scope and Aims

Bringing regenerative medicine from *bench to bedside* is a complex process covering basic, patient-oriented and public health research with regulatory and ethical considerations, and involving various actors including pharmaceutical and biotechnology companies and competent regulatory authorities. REMEDIC aims to put in place a network to facilitate the transfer of knowledge among basic researchers, clinicians and industrial partners, gather information on the current regulations, standards and patents in regenerative medicine and map the current technical research and development resources (see Box 1 on page 5 for a summary of the aims). REMEDIC is led by a Steering Committee composed of a Chair, Vice-Chair and 11 other members representing the national organisations that support the programme and these members, all of whom are researchers in the field of regenerative medicine, have the primary objective of ensuring that the high-level scientific objectives outlined below are achieved. They are also responsible for the management of the programme activities and the promotion of these activities as widely as possible within the larger community of regenerative medicine and within their own country, ensuring that their communities benefit from REMEDIC.

With regard to the research objectives, there will be a particular focus on mesenchymal (stromal) stem cells (Figure 3) and their differentiated derivatives. These cells, endogenously recruited, freshly isolated or expanded *in vitro*, should be able to replace, restore, repair or regenerate tissues. Understanding the basic biology of cell differentiation, blood and lymphatic vessel development and nerve in-growth (Figure 4) are essential for achieving these ambitious aims. Such cells can be implanted on the surface or within intelligent, drug-releasing and bioresorbable scaffolds, which melt




Figure 3. Stromal cells and their differentiated derivatives: Mesenchymal (stromal) stem cells (blue nuclei) containing heat shock protein (granular orange cytoplasm) editing collagen produced to the extracellular matrix (green fibres). Courtesy of Professor Yrjö T. Konttinen.




Figure 4. Basic biology of nerve in-growth: Cortical neurons in fluorescence microscopy after staining with anti-Tau antibodies (green) and DAPI (blue nuclei). *Tau* is a neuronal microtubule associated protein found predominantly in nerve fibres and DAPI is a fluorescent stain that binds strongly to DNA. Courtesy of Dr. Ana Paula Pêgo.

away and are *in toto* replaced by regenerated tissue<sup>1</sup>. Biomaterial-guided tissue regeneration and nano surface technologies can be used to regulate matrix-cell interaction. Currently, hot topics in the field are cartilage repair and bone biology – with applications for diseases such as arthritis and osteoporosis and various types of bone and joint trauma, like for example hip fractures and knee injuries. There are many other applications that range from neurological, ophthalmological and otorhinolaryngological to gastroenterological and cardiological applications. Cell therapy, and if appropriate, in combination with existing (minimally invasive) surgical procedures, forms an important research objective.

As the regenerative medicine field has developed and expanded so rapidly, the view of the field is somewhat hazy, so clarification of the unmet needs of society, academia and companies (pharma and biotech), is necessary to focus interest and funding towards the most important and achievable goals.

Furthermore, as gene, cell therapies and hybrid products have been introduced in a rapid succession, there is need to collect and analyse the rules and standards, which regulate the development, application and marketing of regenerative medicine.

Collection of information on the available equipment and methods used in regenerative medicine has not yet been performed. Due to its inter-disciplinary nature and relevance in many fields of medicine, the need for clean room space and excellent clinical research centres is very high. For the latter, the European Clinical Research Infrastructures Network (ECRIN), will serve as a useful resource centre<sup>2</sup>. Some of the technologies and procedures are so specialised that individual groups and centres cannot maintain them all. REMEDIC will gather information on these current technical R&D resources for the research community.

## Activities




Figure 5. The violet cells are rat mesenchymal stromal cells, which are transgenic for the human placental alkaline phosphatase, in the knee joint of a bone marrow-transplanted, marker tolerant rat knee. Odörfer K. I. *et al.* Marker tolerant, immunocompetent animals as a new tool for regenerative medicine and long-term cell tracking, BMC Biotechnol. 7:30 (2007).

Another key aim is to network institutions, laboratories and companies across Europe to generate collaborations to define and develop research projects at the frontiers of this field and potentially implement them through joint grant applications either during the course of REMEDIC or shortly afterwards. Building such consortia takes time and the activities of the programme should ensure that partners with the relevant experience and technological expertise are linked together.

### Box 1:

#### REMEDIC Aims

1. To facilitate the exchange of ideas and know-how across disciplines in the area of mesenchymal (stromal) and other stem cells;
2. To review the regulatory laws, rules and standards governing the use of regenerative medicine;
3. To map the unmet population, academia and company needs in regenerative medicine and the current R&D resources (e.g. instruments, analysis techniques);
4. To assist researchers in the field of regenerative medicine in preparing cross-disciplinary coordinated research projects.

### References

1. ESF-EMRC Scientific Forward Look on Nanomedicine, Chapters 2.1.3 & 4.2.1 (2005). [www.esf.org](http://www.esf.org)
2. ECRIN ([www.ecrin.org](http://www.ecrin.org)) is one of six research infrastructures identified by the European Strategy Forum on Research Infrastructures (ESFRI) in the biomedical domain. <http://cordis.europa.eu/esfri/home.html>

In order to achieve the aims outlined above, the following activities will be undertaken during the duration of the programme:

- **Workshops** – it is envisaged that there will be a workshop each year of the programme, either stand alone or as part of a larger conference for added synergy, focusing on key aspects of mesenchymal stem cells, their differentiated derivatives and potential clinical applications. The first workshop on Heart Regeneration took place on 15-17 August 2008 in Helsinki, Finland.

- **Short-term (up to 15 days) and exchange (from 15 days up to 6 months) visits** – a particular emphasis will be placed on these visits, to allow researchers to share expertise and techniques in this multi-disciplinary field. Applications will be open to the community of researchers in the field, as long as the proposed research is relevant to the aims of REMEDIC.

- **Reviews** – state-of-the-art reviews based on analysis of literature and patent databases will be prepared for peer-reviewed journals.

- **Rules and Standards** – a review of the regulatory laws, rules and standards governing the use of regenerative medicine will be prepared and made available on the dedicated website.

- **Mapping of needs and available resources** – this will be undertaken within the first two years of the programme and made available for the regenerative medicine community.

- **Internet platform** – there will be a dedicated internet platform to act as the main tool for distribution of information on REMEDIC, its advancement and results. It will also serve as a resource to the entire community, including for example a register of future project partners for joint proposal applications. Dissemination of information is aimed not only at the research community but also at the public, authorities and other key stakeholders.

## Funding

ESF Research Networking Programmes are principally funded by the Foundation's Member Organisations on an *à la carte* basis. Regenerative Medicine "REMEDIC" is supported by:

- **Fonds zur Förderung der wissenschaftlichen Forschung in Österreich (FWF)**  
*Austrian Science Fund, Austria*
- **Fonds voor Wetenschappelijk Onderzoek – Vlaanderen (FWO)**  
*Research Foundation – Flanders, Belgium*
- **Forsknings- og Innovationsstyrelsen (FIST) – Forskningsrådet for Sundhet og Sygdom (FSS)**  
*Danish Agency for Science, Technology and Innovation – Medical Science Research Council, Denmark*
- **Suomen Akatemia/Finlands Akademi**  
*Academy of Finland, Finland*
- **Deutsche Forschungsgemeinschaft (DFG)**  
*German Research Foundation, Germany*
- **Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) – Nederlandse Organisatie voor Gezondheidsonderzoek en Zorginnovatie (ZonMw)**  
*Netherlands Organisation for Scientific Research – Netherlands Organisation for Health Research and Development, The Netherlands*
- **Norges Forskningsråd**  
*Research Council of Norway, Norway*
- **Fundação para a Ciência e a Tecnologia (FCT)**  
*Foundation for Science and Technology, Portugal*
- **Consiliul National al Cercetării Stiintifice din Invatamantul Superior (CNCSIS)**  
*National University Research Council, Romania*
- **Slovenská Akadémia Vied (SAV)**  
*Slovak Academy of Sciences, Slovakia*
- **Consejo Superior de Investigaciones Científicas (CSIC)**  
*Spanish National Research Council, Spain*
- **Comisión Interministerial de Ciencia y Tecnología (CICYT)**  
*Interministerial Committee on Science and Technology, Spain*
- **Vetenskapsrådet (VR)**  
*Swedish Research Council, Sweden*
- **Schweizerischer Nationalfonds (SNF)**  
*Swiss National Science Foundation, Switzerland*

## Steering Committee

### **Professor Yrjö T. Konttinen** (Chair)

Department of Medicine  
Institute of Clinical Medicine  
Biomedicum Helsinki  
PO Box 700 (Haartmaninkatu 8)  
00029 HUS • Finland  
Tel: +358 9 191 25210  
Fax: +358 9 191 25218  
Email: yrjo.konttinen@helsinki.fi

### **Associate Professor Gerjo JVM van Osch** (Vice-Chair)

Departments of Orthopaedics & Otorhinolaryngology  
Erasmus MC, University Medical Center Rotterdam  
Dr Molewaterplein 50  
Office EE16-55  
PO Box 2040  
3000 CA Rotterdam • The Netherlands  
Tel: +31 10 7043661  
Fax: +31 10 7044690  
Email: g.vanosch@erasmusmc.nl

### **Professor Kristina Arvidson**

Center for Clinical Dental Research Faculty  
of Medicine and Dentistry  
University of Bergen  
Årstadvn. 17  
5009 Bergen • Norway  
Tel: +47 55 58 66 41  
Fax: +47 55 58 64 87  
Email: Kristina.Arvidson-Fyrberg@iko.uib.no

### **Professor Reinhold G. Erben**

Institute of Pathophysiology  
Veterinärplatz 1  
1210 Vienna • Austria  
Tel: +43 1 250 77 4550  
Fax: +43 1 250 77 4599  
Email: reinhold.erben@vu-wien.ac.at

### **Professor Enrique Gomez-Barrena**

Department of Orthopaedic Surgery  
Hospital Fundación "Jimenez Díaz"  
Avda. Reyes Católicos 2  
Madrid 28040 • Spain  
Tel: +34 91 5504826  
Fax: +34 91 5431071  
Email: enrique.gomezbarrena@uam.es,  
egbarrena@telefonica.net

### **Professor Moustapha Kassem**

Department of Endocrinology  
University Hospital of Odense  
5000 Odense C • Denmark  
Tel: +45 6541 1606  
Fax: +45 6591 9653  
Email: moustapha.kassem@ouh.fyns-amt.dk

---

**Professor Katarina Le Blanc**

Hematology Centre  
Division of Clinical Immunology  
Karolinska University Hospital Huddinge F79  
141 86 Stockholm • Sweden  
Tel: +46 8 585 813 61  
Fax: +36 8 746 66 99  
Email: Katarina.Lebanc@ki.se

**Professor Frank Luyten**

Department of Musculoskeletal Sciences  
University of Leuven (K.U. Leuven)  
Herestraat 49  
3000 Leuven • Belgium  
Tel: +32 16 34 25 41  
Fax: +32 16 34 25 43  
Email: frank.luyten@uz.kuleuven.ac.be

**Dr. Ana Paula Pêgo**

INEB – Institute of Biomedical Engineering  
Laboratory of Biomaterials  
University of Porto  
Rua do Campo Alegre, 823  
4150-180 Porto • Portugal  
Tel: +351 22 607 4988  
Fax: +351 22 609 4567  
Email: apeg@ineb.up.pt

**Professor Dominique Pioletti**

Institute of Bioengineering Laboratory  
of Biomechanical Orthopedics  
École Polytechnique Fédérale de Lausanne (EPFL)  
1015 Lausanne • Switzerland  
Tel: +41 21 693 83 41  
Fax: +41 21 693 86 60  
Email: dominique.pioletti@epfl.ch

**Professor Laurentiu Popescu**

“Victor Babes” National Institute of Pathology  
& Department of Cellular and Molecular Medicine,  
“Carol Davila” University of Medicine and Pharmacy  
Bucharest • Romania  
Tel: +40 21 319 4530  
Fax: +40 21 312 4885  
Email: lpopescu@jcmm.org, LMP@jcmm.org

**Professor Gustav Steinhoff**

Institute for Regenerative Medicine  
and Stem Cell Therapy (IRMED)  
Biomedical Research Centre Rostock (BMFZ)  
Schillingallee 68  
18057 Rostock • Germany  
Tel: +49 381 203 57880  
Fax: +49 381 494 6102  
Email: steinhoff@irmed.de

**Dr. Ivo Vanicky**

Institute of Neurobiology  
Slovak Academy of Sciences  
Soltésovej 4  
040 01 Kosice • Slovakia  
Tel: +421 55 678 5069  
Fax: +421 55 678 5074  
Email: vanicky@saske.sk

**External Coordinator****Eija Kaila B.Sc.**

Institute of Clinical Medicine  
Biomedicum Helsinki  
PO Box 700 (Haartmaninkatu 8)  
00029 HUS • Finland  
Tel: +358 9 191 25237  
Fax: +358 9 191 25218  
Email: eija.kaila@helsinki.fi

**EMRC Standing Committee Representative****Professor Isabel Varela-Nieto**

Spanish National Research Council (CSIC)  
Institute of Biomedical Investigations “Alberto Sols”  
C/Arturo Duperier 4  
28029 Madrid • Spain  
Tel: +34 91 585 4422  
Fax: +34 91 585 4401  
Email: ivarela@iib.uam.es

---

**ESF Liaison****Dr. Fiona Kernan**

Science

**Ms. Blanche Facchini-Schaller**

Administration

European Medical Research Councils (EMRC)  
European Science Foundation  
1 quai Lezay-Marnésia  
BP 90015  
67080 Strasbourg cedex • France  
Tel: +33 (0)3 88 76 71 18  
Fax: +33 (0)3 88 37 05 32  
Email: bfacchini@esf.org

For the latest information on this Research Networking  
Programme consult the REMEDIC website:

**[www.esf.org/remedic](http://www.esf.org/remedic)**

